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FVIII by-passHaemophilia-A is characterized by deficiency of FVIII, but the bleeding diathesis is not a mere reflection
low FVIII activity. The pathophysiology of haemophilic bleeding diathesis is a complex interplay between
defective procoagulant function and up-regulated fibrinolysis. Moreover, haemophilic bleeding diathesis
is frequently compounded by treatment-related and infective complications such as FVIII inhibitors, hep-
atitis, HIV infection, non-steroidal anti-inflammatory drugs (NSAID) induced gastritis, and infective
mucosal injuries such as H pylori gastritis and intestinal and urinary helminthiasis. Hence, pathophysi-
ology of haemophilic bleeding is multi-factorial, encompassing both FVIII and non-FVIII haemostatic
defects. Currently available literature on pathophysiologic roles of non-FVIII haemostatic defects in hae-
mophilia is fragmented. This articles is aimed at providing a composite and comprehensive review of the
roles of non-FVIII haemostatic defects and their therapeutic implications in haemophilic bleeding diathe-
sis, which will enable a holistic approach towards clinical management of the bleeding diathesis. This is
necessary because FVIII therapy alone maybe insufficient in managing complicated haemophilic bleeding
unless compounding non-FVIII-related haemostatic dysfunctions and comorbidities are identified, tar-
geted and treated. This will necessitate appropriate use of non-FVIII therapeutic modalities, which may
include anti-fibrinolytic agents, FVIII by-passing agents, immune modulation, and anti-microbial agents.
Lots of work has been done in the areas of non-FVIII agents and FVIII by-pass therapy in the management
of haemophilia, but more research is needed to validate many of these targeted therapeutic techniques.
Meanwhile, healthcare personnel must consider the roles of both FVIII and non-FVIII haemostatic defects
when evaluating haemophilic bleeding diathesis for the purpose of choosing appropriate and optimal
treatment options.
 2018 Ain Shams University. Production and hosting by Elsevier B.V. This is an open access article under
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Haemophilia-A is inherited as an X-linked recessive disorder
characterized by lifelong bleeding diathesis due to deficiency of
FVIII, which leads to insufficient formation of tenase, reduced gener-
ation of thrombin, impaired fibrin deposition and poor clot forma-
tion [1]. Although low FVIII level is the fundamental initiator of
bleeding diathesis in haemophilia-A, the pathophysiology of the
haemophilic bleeding diathesis is not a simple reflection of poor clot
formation due to low level of FVIII. The pathophysiology of the hae-
mophilic bleeding diathesis is in fact a complex interplay between a
defective procoagulant function initiated by low FVIII activity and
several non-FVIII related haemostatic dysfunctions. These non-
FVIII related haemostatic dysfunctions include general inability of
the extrinsic pathway to compensate for low thrombin generation
by the intrinsic defect, local attenuation of the extrinsic pathway
by local inhibitors such as tissue factor pathway inhibitor (TFPI) in
the joints [2], general up-regulation of the fibrinolytic pathway
due to low thrombin burst with inadequate activation of thrombin
activable fibrinolysis inhibitor (TAFI) [3], and local up-regulation
of the fibrinolytic pathway by local activators of fibrinolysis
such as urokinase-plasminogen activator (uPA) and tissue-
plasminogen activator (tPA) within the urinary tract [4,5] and the
oral cavity [6]. Moreover, the haemophilic bleeding diathesis is fre-
quently compounded by incidentally acquired pro-haemorrhagic
treatment-related complications that range from FVIII inhibitors
[7] to chronic liver disease due to viral hepatitis [8], HIV-
associated thrombocytopenia [9], and non-selective non-steroidal
anti-inflammatory drugs (NSAIDs) induced gastritis and thrombo-
cytopathy [10] on the one hand, and the acquisition of environmen-
tally ubiquitous pro-haemorrhagic infectious diseases that range
from Helicobacter pylori gastritis [11] to tropical diseases such as
intestinal helminthiasis [12] and urinary schistosomiasis [13] on
the other hand. There is therefore the need for haemophilia health-
care providers to have comprehensive understanding of all of these
non-FVIII related issues and appreciate the pathophysiologic mech-
anisms through which they contribute to the haemophilic bleeding
diathesis. This is necessary because only proper understanding of
these haemostatic defects will enable a holistic approach towards
solving the lifelong bleeding problems of the haemophilia patients.
This is necessary because FVIII therapy alone maybe insufficient in
the management of complicated haemophilic bleeding diathesis
unless compounding non-FVIII related haemostatic dysfunctions
and comorbidities are identified, targeted and treated. The currently
available literature onnon-FVIII relatedhaemostaticdysfunctions in
haemophilia and their relationship to targeted management strate-
gies are fragmented. Hence, the need for an updated critical apprai-
sal to harmonize these important issues in a composite review.Therefore, the aim of this review is twofold. The primary aim is
to conduct a comprehensive harmonized review of various compo-
nents of the haemophilic bleeding pathophysiology in a stepwise
sequential manner starting from physical triggers of bleeding to
FVIII deficiency and proceeding sequentially to subsequent haemo-
static dysfunctions beyond FVIII deficiency (the non-FVIII related
issues). The secondary aim is to review, where appropriate, the
pathophysiologic relationships between individual components
of non-FVIII related haemostatic dysfunctions and targeted man-
agement strategies for haemophilia. Hence, in this review we con-
ducted a broad but concisely critical appraisal of the various non-
FVIII related pathophysiologic mechanisms that act singly or in
concert in the causation and/or aggravation of haemophilic bleed-
ing diathesis with special reference to functional perturbations of
normal haemostasis within the context of traumatic and infective
tissue damage and vascular injury, primary and secondary
haemostasis, and the fibrinolytic system as outlined in Table 1.
2. Triggers of haemophilic bleeding: Spontaneous versus non-
spontaneous
The severity of haemophilia is largely determined by the extent
to which different mutations abolish functional FVIII production
[14]. Consequently, the clinical severity of the disease and bleeding
rates significantly correlates with residual FVIII levels, which is
classified as severe (FVIII level < 1%), moderate (FVIII level 1–5%)
or mild (FVIII level 6–40%) [14]. Severe haemophilia is typically
associated with the null mutations, and is clinically characterized
by high frequency of bleeding episodes that occur spontaneously
[14]. Whereas mild and moderate haemophilia are associated with
less severe non-null mutations, and are clinically characterized by
less frequent bleeding episodes that are usually provoked by trau-
matic events [14]. The conventional terms ‘spontaneous bleeding’
and ‘trauma-induced bleeding’, have for a long time been accepted
terminologies in haemophilia literature. Nonetheless, every bleed-
ing episode is almost certainly triggered by some type and degree
of trauma [15]. Therefore, in reality every haemophilic bleeding is
triggered either by significant trauma (referred to as trauma-
induced bleeding) or insignificant trauma (referred to as sponta-
neous bleeding) [15]. Hence, a recent study has revealed that the
so-called ‘spontaneous bleedings’ are actually triggered by trivial
trauma incurred during normal routine physical activities [15].
3. Trauma, tissue damage and vascular Injury: Simultaneous
activation of primary, secondary and tertiary haemostasis
The physiological consequences of trauma, tissue damage and
vascular injury include bleeding and activation of haemostatic
Table 1
Pathophysiology of haemostatic abnormalities of bleeding diathesis in haemophilia-A.
Haemostatic stages and events Pathophysiologic implications in haemophilic bleeding diathesis
Trauma, tissue damage and vascular injury (1) Vascular endothelial injury causes collagen exposure
(2) Tissue damage releases TF and tPA.
Primary haemostasis Triggered by collagen contact activation of platelet.
But platelet function maybe partially impaired due to:
(1) Low thrombin-mediated platelet activation
(2) Effect of immune complexes and prostacyclin on platelets
Secondary haemostasis: Intrinsic pathway (1) Triggered by collagen contact activation of FXII
(2) But cascade is blocked by FVIII deficiency causing:
(a) Decreased tenase formation
(b) Decreased prothrombinase formation
(c) low thrombin generation
Secondary haemostasis: Extrinsic pathway Triggered by interaction of TF and FVII.
But overall extrinsic pathway activity is insufficient to compensate for the low thrombin generation
by intrinsic pathway
Compensatory failure by extrinsic pathway Persistent low thrombin generation causes low thrombin burst
Low thrombin burst Consequences of low thrombin burst include:
(1) Inadequate activation of platelets
(2) Inadequate activation of FV: low prothrombinase production
(3) Inadequate activation of FXIII: uncross-linked loose fibrin
(4) Inadequate activation of TAFI: de-regulation of fibrinolysis
Tertiary haemostasis: fibrinolysis There are two important fibrinolytic pathways:
(1) Collagen contact activation pathway produces FXIIa from FXII (note: FXIIa is fibrinolytic)
(2) tPA pathway produces plasmin from plasminogen
Fibrinolytic effects of both (1) and (2) above are deregulated by inadequate activation of TAFI due to
low thrombin burst
Naturally occurring aggravators of haemophilic bleeding
diathesis
There are three areas of clinical Significance:
(1) TFPI Production in Joints Aggravates Haemarthrosis
(2) Fibrinolytic activity in saliva aggravates oral bleed
(3) Fibrinolytic activity in urine aggravates urinary tract bleed
Treatment-related complications that aggravate haemophilic
bleeding diathesis
Immunologic, infective and haemostatic issues:
(1) FVIII Inhibitors aggravate all types of Bleed
(2) CLD due to viral hepatitis aggravates all types of bleed
(3) HIV-thrombocytopenia aggravates all types of bleed
(4) NSAID thrombocytopathy may Aggravates all Types of Bleed (but more effect on
Gastrointestinal tract bleed)
Infection-related mucosal injuries that aggravate haemophilic
bleeding diathesis
Microbes that damage mucosa and/or secrete anticoagulants:
(1) H Pylori bacteria: aggravates gastrointestinal bleed
(2) Intestinal helminths: aggravates gastrointestinal bleed
(3) Urinary schistosomes: aggravates urinary tract bleed
TF = Tissue Factor; TFPI = Tissue Factor Pathway Inhibitor; tPA = Tissue Plasminogen Activator; TAFI = Thrombin Activable Fibrinolysis Inhibitor; CLD = Chronic Liver Disease;
NSAID = Non-steroidal Anti-inflammatory Drug.
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injury expose tissue factor, tPA, subendothelial collagen and
microfibrils to the blood, which lead to simultaneous activation of
the primary pathway (via contact activation of platelets) [16], the
intrinsic pathway (via contact activation of FXII) [17], the extrinsic
pathway (via FVII activation by tissue factor) [18] and the fibri-
nolytic pathway (via plasminogenactivation by tPA) [19].Moreover,
the activity of fibrinolytic pathway is augmented by contact-
activation of FXII because FXIIa is a pro-fibrinolytic factor and an
important component of the fibrinolytic pathway [20] (see also Sec-
tion 10 below). The pathophysiology of bleeding diathesis in
haemophilia-A is significantly affected by the extent to which these
haemostatic pathways are inhibited or potentiated in the process of
platelet activation and platelet plug formation (primary haemosta-
sis), thrombin generation and fibrin deposition (secondary
haemostasis), and plasminogen activation and fibrin degradation
(tertiary haemostasis) as highlighted in subsequent paragraphs.4. Primary haemostasis within the context of haemophilia
Primary hemostasis is generally presumed to be normal in
haemophiliacs. But this presumption may not be entirely true.
However, haemophilia is characterized by insufficient generation
of thrombin that is needed for platelet activation and aggregation,
both of which are important in primary platelet plug formation[21], exposure of platelet membrane-associated procoagulant
phospholipids [22], and the assemblage of tenase and prothrombi-
nase complexes of the secondary haemostatic pathways [23].
Therefore, low thrombin generation which is a haemostatic hall-
mark of haemophilia [1], should be expected to adversely affect
both primary (reduced platelet activation and aggregation) and
secondary (reduced tenase and prothrombinase formation)
haemostasis. Accordingly, some studies have suggested that
diminished thrombin mediated platelet activation may contribute
to the haemophilic bleeding diathesis [24]. It is therefore not sur-
prising that some studies also reported that severe haemophiliacs
with higher levels of platelet procoagulant activity had milder clin-
ical phenotypes in comparison with severe haemophiliacs who had
relatively lower platelet procoagulant activity [25]. The exact
mechanism responsible for elevation of platelet procoagulant
activity as reported in some haemophiliacs [25] is not precisely
known, but it is presumed to be related to the so-called ‘compen-
satory platelet activation’ that is thought to occur during haemo-
philic bleeding events [26–28]. However, other studies have
refuted the compensatory platelet activation hypothesis and found
no differences in the levels of markers of platelet activation
between severe haemophiliacs and controls in both clinical [29]
and experimental [30] settings. In related research developments,
some researchers investigated the roles of so-called ‘coated’ or
‘super-activated’ platelets in reducing haemophilic bleeding ten-
dencies [31,32]. These ‘coated’ or ‘super-activated’ platelets refer
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tively charged membrane procoagulant phospholipids that are
thus reportedly associated with fewer bleeding episodes and
milder clinic phenotypes [31,32]. Again, in contrast to these find-
ings, another study found no difference in levels of ‘coated’ plate-
lets between severe hemophiliacs with mild and severe bleeding
phenotypes [33].
Studies on bleeding time in haemophiliacs also yielded incon-
sistent results. Earlier studies have reported that bleeding time
was prolonged in a significant proportion of haemophiliacs, includ-
ing children and young adults [34,35]. These two studies suggested
that the prolongation in bleeding times in haemophiliacs might be
due to some unidentified intrinsic platelet defects and malfunc-
tions [34,35]. But a subsequent study suggested that circulating
immune complexes and high levels of vascular prostacyclin (an
anti-platelet aggregation agent), rather than intrinsic platelet
defects might be linked to the prolonged bleeding times observed
in some haemophiliacs [36]. The origin of these circulating
immune complexes has not been precisely identified, but they
are probably induced by humoral immune response to antigenic
impurities contained in FVIII concentrates [36]. Hence, it was
suggested that prostacyclin-induced defective vascular function
mediated by the circulating immune complexes might be the
pathophysiologic mechanism underlying the prolongation of
bleeding time in some haemophilia patients [36].
It therefore appears that platelet functions may not be entirely
normal in haemophilia [37]. However, the inconsistencies that exist
in the literature [37] regarding the associations between platelet
functions, bleeding time, bleeding tendencies and clinical pheno-
types in haemophiliacs call for more research in this area of study.5. Secondary haemostasis: Intrinsic pathway within the context
of haemophilia
The physiological activation of the intrinsic pathway is initiated
by vascular endothelial injury with exposure of subendothelial col-
lagen [38]. The intrinsic pathway is thus triggered by contact acti-
vation of FXII by collagen [17], which is facilitated by the
participation of high molecular weight kininogen and prekallikrein
in the contact activation process [38]. FXIIa catalyzes the conver-
sion of FXI to FXIa, which subsequently converts FIX to FIXa in
the presence of calcium ions [38]. The haemophilic haemostasis
proceeds normal up till this stage. However, the next stage requires
the provision of catalytic anionic phosphotidylserine-rich phos-
pholipid on membrane surfaces of activated platelets for the
assemblage of intrinsic tenase complex (FIXa, FVIIIa, Ca, Phospho-
lipids) [39]. Unfortunately, the deficiency of FVIII militates against
adequate tenase formation, which is the first and main haemo-
static blockade in the pathophysiology of haemophilia-A [1]. This
perturbation of tenase formation in haemophilia has a number of
collateral effects including decreased prothrombinase formation
and low thrombin generation that ultimately lead to poor fibrin
plug formation, which is the principal cause of the haemophilic
bleeding diathesis [1]. The most rational therapeutic option for
the management of haemophilic bleeding with respect to uncom-
plicated haemostatic blockade created by FVIII deficiency is logi-
cally FVIII concentrate infusion.6. Secondary haemostasis: Extrinsic pathway within the context
of haemophilia
The extrinsic coagulation cascade is physiologically initiated by
exposure of blood to tissue factor (TF), which is the cellular recep-
tor and cofactor for FVII [18]. Binding of FVII to the TF receptor in
the presence of calcium leads to rapid activation and formationFVIIa, which subsequently undergoes auto-catalytic reactions lead-
ing to more production of FVIIa and TF-FVIIa complexes [18]. The
TF-FVIIa complex (extrinsic tenase) drives the cascade through
the common haemostatic pathway by activating FX leading to opti-
mal production of prothrombinase (FXa, FVa, Ca, Phospholipids)
with adequate thrombin generation and effective fibrin deposition
[38]. Hence, the extrinsic pathway cascade does not appear to be
blocked by FVIII deficiency. But the key question is why then does
the extrinsic pathway fail to compensate for the failure of the
intrinsic pathway in haemophilia?7. Compensatory failure by extrinsic pathway to boost
thrombin burst in haemophilia
In accordance with the conventional coagulation cascade, the
TF-FVIIa complex can activate FX, produce prothrombinase, gener-
ate thrombin and deposit fibrin [38]. Hence, the extrinsic pathway
should theoretically be able to compensate for the lack of thrombin
generation by the intrinsic pathway as seen in the case of FXII defi-
ciency in which there is no bleeding diathesis despite prolongation
of clotting time in-vitro [40]. If this compensation is extended to
the deficiencies of other intrinsic clotting factors, the extrinsic
pathway would successfully prevent bleeding diathesis in other
intrinsic pathway deficiencies diseases such as haemophilia-A
(FVII) and haemophilia-B (FIX). Unfortunately this compensation
does not occur in haemophilia A and B. The reason for this compen-
satory failure by the extrinsic pathway in haemophilia is eluci-
dated in a solitary study using an in-vitro continuous-flow
coagulation reactor model, which revealed that adequate concen-
trations of FVIII and FIX are required as essential ‘cofactors’ for
optimal FXa production by the extrinsic pathway, this being the
reason why the extrinsic pathway cannot therefore compensate
for thrombin generation and prevent the bleeding diathesis in both
haemophilia-A and B [41]. Hence, the authors of this solitary pub-
lication curiously referred to ‘haemophilia’ as a ‘defect of the tissue
factor pathway of blood coagulation’ in the title of their interesting
publication [41]. The failure by the extrinsic pathway to compen-
sate for intrinsic pathway thrombin production and the inability
to remedy the haemophilic defect leads to persistence of low
thrombin generation with lack of essential thrombin burst. Low
thrombin burst in haemophilia is associated with certain haemo-
static consequences as outlined in subsequent paragraphs.8. Haemostatic consequences of low thrombin burst in
haemophilia
Because of the significance of thrombin in haemostasis, low
thrombin generation in haemophilia has a number of pathophysi-
ologic consequences on the primary, secondary and tertiary
(fibrinolytic) haemostatic pathways as follows:
8a. Inadequate activation of platelets: Reduced platelet aggregation
The normal physiological response of platelets to thrombin is
mediated by a subset of membrane receptors known as protease-
activated receptors [42]. These receptors are activated on cleavage
by thrombin, initiating the intracellular signaling events needed to
transform mobile, non-adhesive platelets into adhesive cells that
canundergo release reaction and aggregation, andultimatelypartic-
ipate in the growth of an immobile haemostatic plug at the site of
vascular injury [42]. Thus, the recruitment of platelets into a grow-
ing haemostatic plug at the site of vascular injury requires the accu-
mulation of thrombin, which is unfortunately low in haemophilia
[1]. Hence, a laboratory model of whole blood platelet aggregation
stimulated by endogenously generated thrombin suggests that the
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vation [43]. The findings of this study have thus expanded the spec-
trum of haemophilic haemostatic defects and diathesis to include
the primary haemostatic pathway. Therefore, in addition to the
mechanism of immune complex mediated prostacyclin-induced
vascular dysfunction [36] (as detailed in Section 4 above), low
thrombin generation may be an important contributory factor in
the pathogenesis of prolongation of bleeding time as earlier demon-
strated in haemophilic laboratory models [43].
8b. Inadequate activation of FV: Reduced production of
prothrombinase
The prothrombinase complex (FXa, FVa, Ca, Phospholipid) is
assembled on an anionic phospholipid membrane [44]. FVa is thus
an integral part of the prothrombinase complex wherein it func-
tions both as a receptor for FXa and a positive effector of FXa cat-
alytic efficiency in the conversion of prothrombin to thrombin [44].
The activation of FV to FVa is an essential reaction that occurs early
in the process of coagulation and is basically mediated by throm-
bin [45]. Since the initial production of thrombin is not robust,
thrombin-catalyzed activation of FV is an essential positive feed-
back reaction aimed at amplifying the production of prothrombi-
nase and hence thrombin within the blood clotting system [45].
However, inadequate production of tenase (FIXa, FVIIIa, Ca, Phos-
pholipid) due to low FVIII level in haemophilia causes reduced pro-
duction of FXa with a resultant low production of prothrombinase
complex. This scenario leads to persistent low production of
thrombin, which attenuates thrombin-mediated FV activation in
the positive feedback amplification, thereby causing further stag-
nation in the production of prothrombinase. Therefore, low
endogenous production of prothrombinase complex due to
reduced thrombin-mediated activation of FV is an important factor
in the pathogenesis of haemophilic bleeding. This is consistent
with the fact that augmentation of FVa activity within the pro-
thrombinase complex was associated with improved haemostasis
in haemophilia as supported by experimental and clinical evi-
dences [46,47]. Experimental evidence suggested that infusion of
an artificially engineered protein-C-resistant mutant FVa (referred
to as super FVa) increased thrombin generation in FVIII-deficient
plasma in-vitro, and reduced the severity of bleeding events in
FVIII-deficient mice in-vivo [46]. Similarly, clinical evidence sug-
gested that coinheritance of the naturally occurring mutant FV-
Leiden in haemophiliacs leads to relatively high FVa-Leiden activ-
ity, which enhances the prothrombinase complex, and subse-
quently shifts the thrombo-haemorrhagic balance in favour of
greater thrombin generation with a significant reduction in bleed-
ing rates [47]. Thus, the genetically engineered mutant FVa may
have potential therapeutic benefits as a positive modifier of bleed-
ing phenotype in severe haemophiliacs without inhibitors and in
those with inhibitors in whom it may serve as a possible FVIII
by-passing agent [46]. There is therefore the need for further work
and clinical validation in this regard.
The activated protein-C (APC) pathway serves as amajor physio-
logical system for controlling thrombosis by neutralizing excess FVa
and FVIIIa [48]. The essential components of APC pathway include
thrombin, thrombomodulin, protein-C, and protein-S [48]. Throm-
bomodulin functions as a cofactor in the thrombin-induced activa-
tion of protein-C in the anticoagulant pathway by forming a 1:1
stoichiometric complex with thrombin, thereby speeding-up the
protein-C activation several fold [49]. It is therefore possible to spec-
ulate that inhibiting the APC pathway may be a future strategy in
developing next-generation therapeutic targets for haemophilia
treatment. This speculation is corroborated by the work of some
researchers who designed anti-APC serpins that led to significant
reduction in the neutralization of FVa, resulting in increased throm-bin generation, restoration of fibrin deposition and normalization of
bleeding in haemophilic mice [50]. In a similar development, in-
vitro use of FV-stabilizing Fab fragments resulted in enhanced
thrombin generation and clotting times in the blood of severe
haemophilia-A patients [51]. However, additional studies are
needed to further characterize how modulating the APC pathway
may prove beneficial in developing new and safe therapeutic mod-
els for uncomplicated severe haemophiliacs and also as a potential
by-passing strategy for cases complicated by FVIII inhibitors.8c. Inadequate activation of FXIII and TAFI: Reduced fibrin stability
and increased fibrin degradation
Besides formation of fibrin clot, thrombin also prevents clot
lysis in two ways. First, thrombin activates FXIII that mediates
transamidation reactions leading to ligation of adjacent fibrin
monomers and the production of cross-linked fibrin, which is more
resistant to plasmin degradation [52]. Second, thrombin causes
activation of TAFI, which is a potent inhibitor of fibrinolysis and
promoter of clot stability [3]. Therefore, thrombin burst is impor-
tant in protecting fibrin clot against premature lysis by the dual
effect of facilitating cross-linkage of fibrin and activating TAFI.
Hence, lack of sufficient thrombin burst in haemophilia would be
expected to cause insufficient cross-linkage of fibrin resulting in
ease of lysis [52] on the one hand, and sub-optimal activation of
TAFI resulting in defective down regulation of fibrinolysis with
high rate of fibrin degradation [3] on the other hand. Accordingly,
a study has demonstrated that supra-physiological concentrations
of FXIII stabilizes clots in in-vitro blood samples obtained from
haemophiliacs by improving fibrin resistance to tPA-induced fibri-
nolysis even at very low concentrations of FVIII [53]. This study
had shown that the addition of FXIII significantly corrected the fib-
rin clot structure, reduced clot permeability and facilitated fibrin
generation [53]. Hence, the result of this study suggested that FXIII
may be a useful adjunct in the treatment of hemophilia-A [53].
Indeed, an earlier study had reported that in addition to being a
useful adjunct in the treatment of haemophilia, FXIII therapy
reduces FVIII concentrate consumption and is thus a cost-
effective regimen for haemophiliacs [54]. This is because FXIII
has a relatively long half-life of about 9 days, which will be associ-
ated with less frequent dosing, high patient convenience with
greater compliance, and lesser therapy-related expenditure, all of
which are hugely advantageous for patients with lifelong bleeding
diathesis such as haemophilia [54]. There is therefore the need for
further research to standardize and validate the use of FXIII in clin-
ical management of haemophilia.9. Helping the extrinsic pathway to compensate for thrombin
production in haemophilia: Targeting the TFPI
As earlier mentioned thrombin generation in haemophilia is
doubly jeopardized by FVIII deficiency in the intrinsic pathway
and the compensatory failure of the extrinsic pathway to ade-
quately boost thrombin generation. Nonetheless, it is conceivable
that a fraction of the total amount of thrombin generated in hae-
mophilia might still be generated via the TF pathway extrinsic
tenase (FVIIa, TF, Ca, Phospholipids), which is strictly regulated
by TFPI [18]. Hence, it can be presumed that haemophilic bleeding
can be reduced by inhibiting the negative modulatory effect of TFPI
[55]. This presumption is supported by the discovery and
characterization of the anticoagulant TFPI, which has led to the
realization that inhibition of TFPI activity could restore thrombin
generation and functional hemostasis through the extrinsic path-
way even in the absence of optimal levels of FVIII or FIX [55]. There
are currently several investigational models and therapeutic
290 U.A. Ibrahim, S.G. Ahmed / The Egyptian Journal of Medical Human Genetics 19 (2018) 285–295agents that can theoretically and potentially inhibit TFPI and treat
hemophilia in the future [55]. Meanwhile, some researchers have
already preliminarily demonstrated that monoclonal antibodies
against TFPI can restore hemostasis in haemophilic mouse model
[56] and in volunteer human haemophilia patients [57]. The poten-
tial clinical usefulness of monoclonal anti-TFPI for the treatment of
haemophilia is thus under active investigation.10. Tertiary haemostasis: Fibrinolysis within the context of
haemophilia
As expected from normal physiological perspective, the local
tissue damage and vascular endothelial injury at the site of bleed-
ing would activate the fibrinolytic pathway in two ways. First, local
tissue injury would release tPA, which would then convert plas-
minogen to plasmin [19]. Second, vascular injury would expose
sub-endothelial collagen, which would lead to contact activation
of FXII to FXIIa [17], noting that FXIIa is a pro-fibrinolytic factor
and an important component of the fibrinolytic pathway [20].
Therefore, the fibrinolytic pathway in haemophiliacs is fully trig-
gered via the activation of both tPA and FXII in the usual physiolog-
ical manner [17,19]. However, the physiologically important
thrombin-mediated activation of TAFI, which is a potent inhibitor
and negative modulator of fibrinolysis and promoter of clot stabil-
ity [3], does not occur at sufficient level in haemophilia because of
inadequate thrombin generation [3] as previously described in
more detail (see also Section 8c above). Therefore, the fibrinolytic
process is poorly modulated and undesirably up-regulated in hae-
mophilia patients [3]. Thus localized hyper-fibrinolysis of blood
clot at the site of injury is an important contributor to the haemo-
philic bleeding diathesis [3].
In order to improve clot stability, a number of anti-fibrinolytic
agents including epsilon amino caproic acid and tranexamic acid
have been tried in the management of haemophilia [58]. However
tranexamic acid, which reversibly binds the lysine-binding site on
the plasminogen molecule and inhibits the conversion of plas-
minogen to plasmin is more potent than other anti-fibrinolytic
agents [58]. Hence, tranexamic acid has been widely and success-
fully used alone or in combination with FVIII or other anti-
haemophilic agents in the prevention and management of various
haemophilic bleedings due to accidental or surgical trauma in hae-
mophilia patients with and without FVIII inhibitors [58,59]. Thus
we believe it is theoretically possible that a combination of anti-
fibrinolytic agent such as tranexamic acid (an inhibitor of plasmin
production) and FXIII therapy (an augmenter of fibrin resistance to
plasmin) (see also Section 8c above) may act synergistically to pro-
duce greater blockade of the fibrinolytic process in the manage-
ment of severe haemophiliacs especially in those complicated by
inhibitors with frequent severe bleeding. Nonetheless, we reckon
that this dual targeting and blockade of the fibrinolytic process
must be carefully assessed against the risk of developing intravas-
cular thrombosis, hence, the need for more studies in this area.
11. Naturally occurring aggravators of haemophilic bleeding
diathesis
There are at least 3 areas of the body where naturally occurring
aggravators of haemophilic bleeding diathesis exist. These include
TFPI in the joints and plasminogen activators in the oral cavity and
the urinary tract as described below.
11a. TFPI production in joints aggravates haemarthrosis
The TFPI is the specific and exclusive inhibitor of tissue factor
pathway [60]. The TFPI is a potent and direct inhibitor of FXa andFXa-dependent inhibitor of the FVIIa-TF complex [60]. The
microvascular endothelium is thought to be the main source of
TFPI [61]. In addition to endothelial cells, it has been shown that
many other vascular wall cells such as mesangial cells, smooth
muscle cells, monocytes, fibroblasts, and cardiomyocytes can also
synthesize TFPI to a lesser extent [62]. After synthesis, TFPI
becomes externalized and attached to the surface of the endothe-
lium where it serves an important physiological function of main-
taining normal endothelial thrombo-regulatory mechanisms for
the prevention of excessive thrombotic tendencies within blood
vessels [60]. Moreover, the synovial cells and chondrocytes have
also been shown to be significant producers of TFPI, which is unde-
sirable in the haemophilic patients [2]. This local production of
TFPI leads to localized intra-articular attenuation of the extrinsic
pathway with resultant aggravation of bleeding tendency within
the haemophilic joints [2]. Hence, the high frequency of
haemarthrosis, which is pathognomonic of severe haemophilia, is
due to local intra-articular production of TFPI [2]. However, there
is a strong optimism that currently ongoing research on the
haemostatic effects of monoclonal anti-TFPI that is being tested
in experimental [56] and clinical [57] haemophilic models (see also
Section 9 above) may eventually reduce the occurrence of crippling
haemarthrosis and arthropathy in haemophilia patients in the very
near future.
11b. Fibrinolytic activity in saliva aggravates oral bleeding
Salivary fibrinolysis due to the presence of plasminogen activa-
tors in the saliva is usually strongly associated with blood sucking
animals such as the vampire bats [63]. However, the human saliva
is to a lesser extent also known to have significant fibrinolytic
potential that may aggravate bleeding even in haemostatically nor-
mal (non-haemophilic) persons after accidental or surgical trauma
within the oral cavity [6]. It is therefore not surprising that oral
cavity bleeding may pause special challenge in the haemophiliac
because the salivary fibrinolytic activity causes undue clot instabil-
ity that aggravates bleeding [64]. Hence, down-regulating the sali-
vary fibrinolysis by local (mouth wash) or systemic use of anti-
fibrinolytic agents have proven to be very effective in controlling
oral cavity bleeding in haemophiliacs [64].
11c. Fibrinolytic activity in urine aggravates urinary tract bleeding
The human urinary tract has long been recognized as major
source of plasminogen activators. It has been demonstrated that
uPA is synthesized by human glomerular epithelial cells and
secreted into the urine [4], while the cellular distribution of tPA
within the prostate gland suggests that the central zone of the
prostate is the selective site of synthesis of tPA, from which it is
secreted into the urine [5]. Functional deductions strongly suggest
that both uPA and tPA are essential in the maintenance of patency
within the urinary tract, wherein they mitigate obstructive pathol-
ogy by catalyzing extracellular proteolysis (to prevent protein pre-
cipitation) and facilitate fibrinolysis (to prevent blood clot
formation) [4,5]. However, this localized up-regulation of the fibri-
nolytic pathway by uPA and tPA within the urinary tract is undesir-
able in haemophiliacs because it causes clot instability and
aggravate bleeding from even trivial injuries within the urinary
tract. However, unlike in the case of haemophilic oral bleeding that
can be treated by down-regulating salivary fibrinolysis through the
use anti-fibrinolytic agents [64], urinary tract bleeding cannot be
treated in the same way because of the possible risk of obstructive
uropathy that may occur as a result of enhancement of fibrin clot
formation by anti-fibrinolytic agents [64]. Hence, FVIII replace-
ment therapy is safer than anti-fibrinolytic agents in treating uri-
nary tract bleeding in haemophilia.
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haemophilic bleeding diathesis
These aggravators of haemophilic bleeding diathesis refer to
acquired aggravators that are only incidentally found in
haemophiliacs. But when they occur, they may negatively affect
systemic haemostasis and cause general increase in the rate of
all types of bleeding without any special predilection for specific
regions or organs of the body. These acquired aggravators are man-
ifestations of immunological, infective and haemostatic complica-
tions of the treatment received by haemophilia patients as
described below.12a. Immunological complications: FVIII inhibitors
The development of FVIII inhibitors is the most devastating
complication of FVIII therapy in haemophilia. The clinical signifi-
cance of FVIII inhibitors is linked to their ability to neutralize FVIII
as a result of which affected patients have increased risk, frequency
and severity of bleeding, with a concomitant sub-optimal response
to factor replacement and a corresponding increase in the demand
for factor concentrate that ultimately raises the intensity and cost
of treatment [7]. The risk of developing FVIII Inhibitor is mainly
related to the type of FVIII mutation [14]. It has been demonstrated
that FVIII gene mutations that are associated with the absence of
the gene product (null mutations) confer higher risk for inhibitor
development, while mutations that are associated with the pres-
ence of the gene product (non-null mutations), confer a lower risk
for inhibitor development [14]. Interestingly, the type of FVIII
mutation also significantly influences the therapeutic response to
immune tolerance induction (ITI) therapy [65]. It appears that
there is an inverse correlation between the risk of inhibitor devel-
opment and success rate of ITI therapy [65]. This is because it has
been demonstrated that FVIII mutations that confer higher risk of
inhibitor development were also significantly associated with
lower success rates of ITI therapy than that seen in patients with
lower-risk FVIII mutations [65]. Apart from FVIII gene mutations,
other genetic factors also contribute to the risk of developing inhi-
bitors. These factors include a positive family history of inhibitors,
ethnicity, and certain polymorphisms in immune modulatory
genes that may increase (eg IL-10 and TNF-alpha genes) or
decrease (eg CTLA-4 gene) the risk of developing inhibitor
[14,66]. The relatively higher incidence of polymorphisms in the
immune modulatory genes for IL-10 and TNF-alpha may partly
explain the higher risk of inhibitor development in blacks and
other non-Caucasian haemophiliacs [67]. Moreover, the role of eth-
nicity and FVIII haplotype variation between donor and recipient in
the development of FVIII inhibitors has been studied among black
hemophiliacs living in Caucasian communities [68]. The study sug-
gested that mismatched FVIII replacement therapy is a risk factor
for the development of FVIII antibodies in black patients receiving
human FVIII derived from Caucasian plasma or rFVIII derived from
genetic template obtained from Caucasian genomes [68]. More-
over, the ABO blood groups play important roles in the risk of inhi-
bitor development as the inheritance of non-O blood groups
appear to confer a higher relative risk of developing FVIII inhibitor,
while blood group-O appears to be a negative regulator of in-vivo
immunogenicity of infused FVIII and hence a protector against the
development of inhibitors [69].
Non-genetic factors are also important in the development of
FVIII inhibitors. It has been suggested that exposure to FVIII in
the presence of immune modulators such as active infections or
vaccinations, as well as tissue damage due to accidental or surgical
trauma have the potential to generate signals that would activate
the antigen-presenting cells and increase the risk of developingFVIII inhibitors [70]. Moreover, treatment-related cofactors, such
as early age at first exposure to FVIII, type of FVIII product and
its inherent immunogenicity, as well as the intensity of treatment,
especially when administered by continuous infusion may signifi-
cantly increase the risk of inhibitor development [70–72].
The management of FVIII inhibitors is both complex and costly.
There are basically three main ways of managing inhibitors viz:
flooding (high dose infusion), immune tolerance induction, and
FVIII by-pass therapy. The feasibility and success of ‘flooding’ ther-
apy depends on the level of inhibitor and intensity of anamnestic
response after re-exposure to FVIII [73]. Patients with low respond-
ing inhibitors (inhibitor level lower than 5 BU/mL) usually have
fewer clinical problems because haemostasis can usually be
ensured by saturating the inhibitor through the administration of
higher ‘flooding’ doses of FVIII [73]. In contradistinction, high
responding (inhibitor level higher than 5 BU/mL) inhibitors are
not amenable to ‘flooding’ therapy with high doses of FVIII, and
hence, alternative haemostatic agents including by-passing agents
are required in such cases [73]. For these reasons, the primary aim
of treatment in such cases is the permanent eradication of the inhi-
bitor by ITI therapy, which will enable effective replacement ther-
apy and make prophylaxis feasible [73]. However, ITI therapy is
costly and fails in about one third of patients [73]. Nonetheless,
the possibility of using Rituximab as an independent immune tol-
erance inducer or an adjunct that may increase response rate in ITI
therapy is being explored [74]. Meanwhile, by-passing agents such
as activated prothrombin complex concentrates (aPCC) and recom-
binant activated factor VII (rFVIIa) are currently the treatment of
choice for the management of bleeding in patients with high titre
inhibitors that cannot afford or have failed ITI therapy [73]. Newer
innovative ways of by-passing FVIII function that awaits further
standardization involves the use of bi-specific recombinant
humanized IgG4 antibody (Emicizumab) [75]. This novel antibody
simultaneously binds factor IX and factor X and bring them into
close proximity, thus providing some of the scaffold–cofactor func-
tion of FVIIIa with a resultant reduction in bleeding rates in
haemophiliacs with FVIII inhibitors as demonstrated in a random-
ized clinical trial [75]. There is no doubt that Emcizumab has the
potential to positively impact haemophilia therapy in the very near
future.
12b. Infective complications: Viral hepatitis, chronic liver disease and
HIV infection
Transfusion of blood or blood products is associated with the
risks of contracting blood born infectious agents such as hepatitis
(B and C) and HIV. The risks of acquiring these infections in the
developed countries have been greatly minimized as a result of
modernization of blood safety protocolswith efficient donor screen-
ing procedures, effective viral inactivation techniques and produc-
tion and use of recombinant blood products [76]. However,
infection risks are particularly high in the tropics where the preva-
lence of blood born infections is high, donor screening procedures
are inadequate, viral inactivation techniques are virtually absent,
and recombinant blood products are unavailable [77]. Both chronic
viral hepatitis and HIV infections can negatively affect the bleeding
rates and clinical phenotypes of infected haemophiliacs by causing
chronic liver disease with multiple coagulation factor deficiencies
[8] and HIV-associated thrombocytopenia [78] respectively. The
liver is the most important source of coagulation factors in the
human body. The hepatocyte is themain producer of all coagulation
factors, except FVIII and vWF that are produced by the hepatic sinu-
soidal cells [79]. Therefore, acquisition of chronic liver disease
essentially transforms haemophilia from a ‘single factor’ deficiency
disorder into a ‘multi-factor’ deficiency disorder, that would not
respond optimally to FVIII therapy alone. Hence, in addition to FVIII
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mentary use of concentrates that contain multiple clotting factors
such as cryoprecipitate [80] and anti-viral immunemodulators such
as alpha interferon [81]. Similarly, acquisition of thrombocytopenia
jeopardizes primary haemostasis and aggravates bleeding in hae-
mophilia [78]. Therefore, HIV-associated thrombocytopenia should
be treated adequately with anti-retroviral agents in conjunction
with immuno-suppressants or immune modulators [78]. However,
in view of their prothrombotic side effects, HIV protease inhibitors
[82] may be particularly advantageous for HIV-infected haemophil-
iacs. This is because the protease inhibitors will certainly treat the
HIV infection and also predictably reduce the haemophilic bleeding
rate as a paradoxical ‘benefit’ of their prothrombotic side effects
[82]. Hence, physicians involved in the management of HIV
infections may consider taking this point into perspective when
‘tailoring’ drug regimen for HIV-infected haemophiliacs especially
for cases that are complicated by thrombocytopenia.12c. NSAID-induced gastritis and thrombocytopathy
Non-steroidal anti-inflammatory drugs are potential aggrava-
tors of bleeding in haemophilia for two reasons. First, NSAIDs are
known to induce gastritis and increase the risk of gastrointestinal
bleeding even in haemostatically normal persons [83], hence it is
not surprising that NSAIDs are associated with increased risk of
gastrointestinal bleeding in haemophiliacs [84]. Second, NSAIDs
cause acquired thrombocytopathy by down-regulating the primary
haemostatic pathway through the inhibition of cyclo-oxygenase,
reduction of thromboxane-A2 production, and attenuation of pla-
telet activation and aggregation [85]. Moreover, because NSAID-
induced thrombocytopathy is a systemic haemostatic problem,
some NSAIDs have also been associated with increased risk of very
serious non-gastrointestinal bleeding complications such as haem-
orrhagic stroke [86]. Therefore, while the haemorrhagic risk of
NSAID consumption may be higher in the gastrointestinal tract,
other organs of the body are not exempted from this risk. Localized
ulcerative effect of NSAIDs on the gastrointestinal tract could be
reduced by proton pump inhibitors [83], however there are no
specific antidotes for the potential haemorrhagic risk that may
arise as a result of systemic thrombocytopathic effect of NSAIDs
on the primary haemostatic pathway [85,86].
These potential bleeding risks call for caution when contem-
plating the use of NSAIDs for the management of pain and inflam-
mation in relation to haemophilic arthropathy or any other
inflammatory condition in haemophilia patients. Studies have
shown that cyclooxygenase-2 (COX-2) inhibitors have comparable
analgesic effect to the traditional non-selective NSAIDs but with
less bleeding risks [87]. Therefore, COX-2 inhibitors provide a suit-
able option for treatment of haemophilic arthropathy [87]. Despite
their relative safety with respect to bleeding, it should be appreci-
ated that COX-2 inhibitors have an increased risk of thrombotic
cardiovascular complications [88]. Although haemophiliacs have
lower risk of thrombotic complications as compared to general
population, nonetheless they are not completely protected from
the cardiovascular risks of COX-2 inhibitors [88]. Therefore, it
seems reasonable to prudently use the lowest possible dose of
COX-2 inhibitors for the shortest period in conjunction with a pro-
ton pump inhibitor in order to further minimize the risk of gas-
trointestinal ulceration and bleeding [87].13. Infection-related mucosal injuries that aggravate
haemophilic bleeding diathesis
These aggravators of haemophilic bleeding diathesis refer to
environmentally ubiquitous global and tropical infectious diseasesthat are incidentally found in haemophiliacs. These infections
specifically aggravate bleeding in the gastrointestinal and urinary
tracts by causing mucosal injury and in some cases by manipulat-
ing the blood coagulation system as described below:
13a. Globally ubiquitous pro-haemorrhagic bacterial Infections:
Helicobacter pylori induced gastrointestinal bleeding
H pylori is a highly ubiquitous bacterial pathogen with global
distribution and approximately half of the world population has
been estimated to be infected, but the risk of infection is higher
in developing countries [89]. When H pylori is ingested, it survives
in the acidity of the gastric fluid, propagates towards the gastric
epithelial cells by flagella-mediated motility, attaches to the
epithelial cells via receptor mediated interaction, and releases tox-
ins that cause inflammatory epithelial damage culminating in pep-
tic ulceration, which increases the risk of gastrointestinal bleeding
even in haemostatically normal persons [89]. H pylori infection is
therefore highly undesirable in haemophiliacs in whom it signifi-
cantly raises the risk, frequency and severity of upper gastroin-
testinal bleeding [11]. For this reason it is pertinent that
haemophiliacs who present with recurrent symptoms of gastritis
and upper gastrointestinal bleeding should be screened for H pylori
infection, and positive cases should be promptly treated with
appropriate antibiotics in order to heal the gastric epithelium, stop
any active bleeding, and reduce future risks of gastrointestinal
bleeding [11]. It must be appreciated that FVIII infusions alone,
without antibiotics, would not be therapeutically sufficient in
these cases. Moreover, continuous infusions without antibiotics
in these cases may even promote the development of FVIII inhibi-
tors since active infections and inflammations are important non-
genetic risk factors for inhibitor development in haemophiliacs
[70].
13b. Tropical pro-haemorrhagic parasitic Infestation: Intestinal and
urinary helminthiasis
Tropical intestinal parasites cause gastrointestinal bleeding by
inducing mucosal injuries leading to a wide spectrum of chronic
or intermittent blood losses that range from occult bleeding to
melena and frank bleeding in association with soil transmitted hel-
minths such as hook worms [90,91], A lumbricoides [92,93], and T
trichiura [94]. In addition to mucosal injuries, some intestinal
helminths have the capacity to manipulate the host haemostatic
system by actively producing anti-coagulants such as anti-FX and
anti-FIX as in the case of hook worms [95]. Therefore, intestinal
helminthiasis is an important risk factor for gastrointestinal bleed-
ing even in haemostatically normal individuals [90–94]. Hence, it is
easy to predict that the haemostatic abnormality in the haemophil-
iac would create a highly pro-haemorrhagic host-parasite relation-
ship, which would increase the vulnerability of haemophilia
patients to the haemorrhagic effects of intestinal helminths.
However, this potentially significant vulnerability have not been
adequately studied because the vast majority of publications on
haemophilia arose from developed nationswhere parasitic diseases
are not endemic. A solitary study conducted in Nigeria on the
subject matter revealed that haemophiliacs with intestinal
helminthiasis had significantly higher frequency of gastrointestinal
bleeding and iron deficiency than their counterparts without
helminthiasis [12]. This study suggests that intestinal helminthiasis
is an important risk factor for frequent and severe gastrointestinal
bleeding in haemophiliacs. Therefore, healthcare personnel in the
tropics should ensure that all haemophiliacs are regularly screened
and treated for intestinal helminthiasis in order to attenuate the
risk and frequency of gastrointestinal bleeding. This is pertinent
since helminthiasis-induced gastrointestinal haemorrhage in the
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FVIII until and unless appropriate anti-parasitic chemotherapy is
instituted.
Urinary schistosomiasis is yet another tropical pro-
haemorrhagic parasitic disease caused by Schistosoma haemato-
bium. The parasites preferentially settle in the vesical plexus
wherein they reproduce, deposit eggs and trigger inflammation that
damages the epithelium and cause haematuria [96]. In addition to
epithelial injuries, S. haematobium parasite is known to secrete ser-
ine protease inhibitors with anti-thrombin properties that manipu-
late the host haemostatic system and escalate the severity of
haematuria [97]. Consequently, urinary schistosomiasis is an
important cause of haematuria and iron deficiency even in haemo-
statically normal persons in the tropics [96,97]. It can therefore be
easily deduced that the haemostatic abnormality associated with
haemophilia would create a highly pro-haemorrhagic host-
parasite relationship, which would make the haemophiliacs partic-
ularly vulnerable to the haemorrhagic effects of urinary schistoso-
miasis. In similarity with intestinal helminthiasis, the significance
of urinary schistosomiasis is not adequately studied because the
vast majority of publications on haemophilia originated from
developed countries in which parasitic diseases are not endemic.
However, a solitary study from Nigeria had revealed that haema-
turia is not uncommon in haemophiliacs and it is mainly caused
by spontaneous haemorrhage or trauma but urinary schistosomia-
sis was responsible for a significant proportion of cases [13]. More-
over, the study revealed that schistosomal haematuria was severer
and caused significant anaemia in contradistinction to spontaneous
and traumatic haematuria that were milder and did not cause sig-
nificant anaemia [13]. This study suggests that urinary schistosomi-
asis is an important risk factor for frequent and severe of urinary
tract bleeding in haemophiliacs infected by the parasite. The result
of this study underscores the need for healthcare personnel in the
tropics to ensure that all haemophiliacs presenting with haema-
turia are properly investigated by urinalysis for early detection
and prompt treatment. This is important because schistosomal
haematuria would not remit even with the use of FVIII infusion
unless the underlying parasitic infection is eradicated by appropri-
ate anti-schistosomal chemotherapy. Moreover, continuous infu-
sions without anti-parasitic drugs in these cases may even induce
the development of FVIII inhibitors since active infections and
inflammations are known to be important non-genetic risk factors
for the development inhibitors in haemophilia patients [70].14. Conclusion
The bleeding diathesis in haemophilia-A is not merely a reflec-
tion of low FVIII activity. The pathophysiology of haemophilic
diathesis is multi-factorial, encompassing both FVIII and non-
FVIII related haemostatic defects. This fact underscores the need
for healthcare providers to have comprehensive understanding of
all of these aetiologic factors and the pathophysiologic mecha-
nisms through which they contribute to the bleeding diathesis.
This is pertinent because only proper understanding of these com-
plex and inter-related haemostatic issues will enable a holistic
approach within the context of currently available treatment
options and therapeutic choices towards solving the lifelong bleed-
ing problems of the haemophilia patients. It should therefore be
appreciated that FVIII therapy alone may be insufficient in the
management of complicated haemophilic bleeding diathesis unless
compounding non-FVIII related haemostatic comorbidities are
identified, targeted and treated with the appropriate non-FVIII
therapeutic modalities, which may include anti-fibrinolytic agents,
FVIII by-passing agents, immunotherapy, immune-modulation,
and anti-microbial agents. Therefore, haemophilia healthcarepersonnel must take into consideration non-FVIII-related patho-
physiologic dysfunctions when clinically evaluating haemophilic
bleeding diathesis for the purpose of choosing optimal and
appropriate treatment options.15. Authorship contributions
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